Liver Disease Chronic
14
3
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (14)
Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).
Validation of Different Methods for HepQuant DuO® Blood Sample Collection
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
cACLD in Patients With Alcohol Use Disorder in the Hospital Detoxification Unit
Effectiveness of Ultrasound in Liver Stiffness and Fat Quantification
Albumin Catabolic Rate Measured by a Stable Isotope
Characterization of Gut Microbiota in Chronic Liver Disease With Decreased Muscle Mass
Efficacy of HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease.
COVID-19 Vaccines in Patients With Chronic Liver Disease
A Phase Ib Clinical Study for rhTPO in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease
Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease
Inspiratory Muscle Training Post-Liver Transplant
Gut Microbiota Metagenomics for Chronic Liver Disease